物理性质
- 产品应用免疫增强剂.治疗胸腺发育不全综合征,运动失调性毛细血管扩张症等免疫缺陷性疾病.国内用于治疗复发性口疮,麻风重症感染等伴有免疫功能低下的患者.不良反应:少数人服用后出现荨麻疹,皮疹等局部过敏反应,偶见头昏发热等全身过敏反应.注射前应做皮试.
- 性质描述本品系小牛,猪胸腺提取得到的一类重要激素.国外主要用胸腺素组分5, 含有多种多肽,相对分子质量为1000-15000.我国用的猪胸腺素组分5是等电点为3.5-9.5的不同蛋白质组成的混合物,相对分子质量在15000以下.胸腺素组分5具有免疫活性,具体含有胸腺素α1,胸腺素α5,胸腺素α7,胸腺素β3和胸腺素β4等活性成分,主要作用是促进T细胞分化成熟,诱导前T细胞(淋巴干细胞)转化为T细胞,并进而分化成为具有各种特殊功能的T细胞亚群,增加和调整机体的免疫功能.胸腺素对热稳定,短时间内加热至80°C,生物活性不降低.
海关参考信息
- 2905122000-异丙醇
2912110000-甲醛
2912120000-乙醛
2915110000-甲酸 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11845970-B2
优先权日:2016-01-15
标 题:Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
发明人:WANG LAI-XI; YANG QIANG; LI TIEZHENG; TONG XIN
权利人:UNIV MARYLAND
摘要:The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.
专利号:WO-9108220-A1
优先权日:1989-12-01
标 题:A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines
发明人:HOUEN GUNNAR; HOLM ARNE
权利人:HOUEN GUNNAR; HOLM ARNE
摘要:Chemical species, particularly peptides, are synthesized by a stepwise, controlled process, in which a proteinaceous substance such as a protein is used as the synthesis substrate. The products obtained by the process can be used e.g. as vaccines against various diseases and as matrix materials or carrier molecules.
专利号:EP-1891104-B1
优先权日:2005-05-04
标题:Solid phase bound thymosin alpha1 and its synthesis
发明人:ALBERICIO FERNANDO; CRUZ LUIS JAVIER; GARCIA RAMOS YESICA; TULLA-PUCHE JUDIT
权利人:LONZA AG
摘要:A method for solid phase synthesis of Thymosin alpha1 is devised.
专利号:US-11459380-B2
优先权日:2017-06-29
标 题 :Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling
发明人:WANG LAI-XI; TONG XIN; LI TIEZHENG
权利人:UNIV MARYLAND
摘要:The present invention provides for a one-pot enzymatic approach which does not require removal of the enzyme and purification of the intermediate after deglycosylation step, and the Endo-S treatment is able to do both deglycosylation and transglycosylation. The one-pot strategy of the present invention enables chemoenzymatic synthesis of an azido-tagged N-glycoform of monocloncal antibodies which could be further modified through orthogonal chemical ligation for various applications.
专利号:US-10370455-B2
优先权日:2014-12-05
标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
发明人:MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
权利人:IMMUNEXT INC
摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.
专利号:EP-0090789-A1
优先权日:1982-03-26
标题 :Chemical DNA synthesis
发明人:ADAMS STEVEN PAUL; GALLUPPI GERALD RUSSELL
权利人:MONSANTO CO
摘要:A process for the production of oligonucleotides such as DNA is disclosed which comprises the phosphite triester method on inorganic solid support in which a hindered dialkylamino nucleoside phosphite having a total of 4 to 6 carbon atoms in the dialkyl group is employed as an intermediate reagent in the synthesis. The solid support preferably is controlled pore glass with a long spacer.